| New therapeutic strategies in HCV: second-generation protease inhibitors. | |
| | |
MedLine Citation:
|
PMID: 23286850 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Telaprevir and boceprevir are the first direct-acting antiviral agents approved for use in HCV treatment and represent a significant advance in HCV therapy. However, these first-generation drugs also have significant limitations related to thrice-daily dosing, clinically challenging side-effect profiles, low barriers to resistance and a lack of pan-genotype activity. A second wave of protease inhibitors are in phase II and III trials and promise to provide a drug regimen with a better dosing schedule and improved tolerance. These second-wave protease inhibitors will probably be approved in combination with PEG-IFN and Ribavirin (RBV), as well as future all-oral regimens. The true second-generation protease inhibitors are in earlier stages of development and efficacy data are anxiously awaited as they may provide pan-genotypic antiviral activity and a high genetic barrier to resistance. |
| | |
Authors:
|
Virginia C Clark; Joy A Peter; David R Nelson |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Liver international : official journal of the International Association for the Study of the Liver Volume: 33 Suppl 1 ISSN: 1478-3231 ISO Abbreviation: Liver Int. Publication Date: 2013 Feb |
Date Detail:
|
Created Date: 2013-01-04 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101160857 Medline TA: Liver Int Country: United States |
Other Details:
|
Languages: eng Pagination: 80-4 Citation Subset: IM |
Copyright Information:
|
© 2012 John Wiley & Sons A/S. |
Affiliation:
|
University of Florida, FL, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Best strategies for global HCV eradication.
Next Document: New therapeutic strategies in HCV: polymerase inhibitors.